UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) --
Merus N.V (https://merus.nl/). (Nasdaq: MRUS), a clinical-stage oncology company
developing innovative, full-length multispecific antibodies (Biclonics(®) and
Triclonics(®)), today announced that Bill Lundberg, M.D., President, Chief
Executive Officer of Merus, will participate in a fireside chat at the Jefferies
Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 a.m. ET.
The webcast of the presentation will be contemporaneously available on the
Investors page (https://ir.merus.nl/event-calendar) of the Company's website.
The archived presentation will also be available there for a limited time after
the event.
About Merus
Merus (https://merus.nl/about/) is a clinical-stage oncology company developing
innovative full-length human bispecific and trispecific antibody therapeutics,
referred to as Multiclonics(®) (https://merus.nl/technology/multiclonics-
platform/). Multiclonics(®) are manufactured using industry standard processes
and have been observed in preclinical and clinical studies to have several of
the same features of conventional human monoclonal antibodies, such as long
half-life and low immunogenicity. For additional information, please visit
Merus' website (https://merus.nl/), X (https://twitter.com/MerusNV) and LinkedIn
(https://www.linkedin.com/company/merus).
Multiclonics(®), Biclonics(®) and Triclonics(®) are registered trademarks of
Merus N.V.
Â